Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have been given a consensus rating of “Moderate Buy” by the twenty-two ratings firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $633.6842.

TMO has been the subject of several recent analyst reports. Argus lifted their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. UBS Group reaffirmed a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. JPMorgan Chase & Co. boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Finally, The Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research note on Tuesday, December 9th. They set a “buy” rating and a $685.00 price target for the company.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $541.94 on Friday. The firm has a market cap of $203.61 billion, a PE ratio of 30.55, a P/E/G ratio of 3.26 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $643.99. The firm has a 50 day simple moving average of $591.73 and a 200-day simple moving average of $541.12.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.45 by $0.12. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business’s revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $6.10 earnings per share. On average, equities analysts expect that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its board has initiated a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 1,058 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the sale, the vice president directly owned 13,087 shares in the company, valued at $7,698,558.62. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. This represents a 36.41% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 114,292 shares of company stock valued at $66,518,754. 0.33% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several hedge funds have recently modified their holdings of TMO. High Note Wealth LLC grew its position in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $29,000. HFM Investment Advisors LLC lifted its holdings in Thermo Fisher Scientific by 341.7% in the 4th quarter. HFM Investment Advisors LLC now owns 53 shares of the medical research company’s stock worth $31,000 after buying an additional 41 shares in the last quarter. Finally, JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $28,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.